Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014010603) PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STRESS URINARY INCONTINENCE OR MIXED INCONTINENCE, AND METHOD FOR SCREENING COMPOUNDS TO BE INCLUDED IN SAID PHARMACEUTICAL COMPOSITION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/010603 International Application No.: PCT/JP2013/068781
Publication Date: 16.01.2014 International Filing Date: 09.07.2013
IPC:
G01N 33/15 (2006.01) ,A61K 31/343 (2006.01) ,A61K 31/381 (2006.01) ,A61K 31/4045 (2006.01) ,A61K 45/00 (2006.01) ,A61P 7/12 (2006.01) ,A61P 43/00 (2006.01) ,C12Q 1/02 (2006.01) ,G01N 33/50 (2006.01) ,C12N 15/09 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15
Medicinal preparations
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
381
having five-membered rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
4045
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
12
Antidiuretics, e.g. drugs for diabetes insipidus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
02
involving viable micro-organisms
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
Applicants:
アステラス製薬株式会社 ASTELLAS PHARMA INC. [JP/JP]; 東京都中央区日本橋本町二丁目5番1号 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411, JP
Inventors:
渡辺 亨 WATANABE, Toru; JP
川端 圭子 KAWABATA, Keiko; JP
渡辺 由香 WATANABE, Yuka; JP
湯山 弘法 YUYAMA, Hironori; JP
増田 典之 MASUDA, Noriyuki; JP
バーガード、エドワード シー BURGARD, Edward C.; US
トール、カール ブルース THOR, Karl Bruce; US
Agent:
森田 拓 MORITA, Hiroshi; 東京都中央区日本橋本町二丁目5番1号 アステラス製薬株式会社 知的財産部内 c/o Astellas Pharma Inc. Intellectual Property, 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411, JP
Priority Data:
2012-15431910.07.2012JP
Title (EN) PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STRESS URINARY INCONTINENCE OR MIXED INCONTINENCE, AND METHOD FOR SCREENING COMPOUNDS TO BE INCLUDED IN SAID PHARMACEUTICAL COMPOSITION
(FR) COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER OU À PRÉVENIR L'INCONTINENCE URINAIRE DE STRESS OU L'INCONTINENCE MIXTE, ET PROCÉDÉ DE CRIBLAGE POUR IDENTIFIER LES COMPOSÉS À INCLURE DANS LADITE COMPOSITION PHARMACEUTIQUE
(JA) 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
Abstract:
(EN) [Problem] To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening compounds to be included in the pharmaceutical composition as the active ingredient. [Solution] The present invention pertains to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence and containing as the active ingredient a compound having a melatonin receptor activation effect. Melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like can be cited as the active ingredient. Also, the present invention pertains to a method that is for screening compounds to be included as the active ingredient in the pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence and that comprises: a step for measuring melatonin receptor activity; a step for measuring the contraction of an excised urethra; and a step for measuring urethral inner pressure.
(FR) L'objectif de cette invention est de pourvoir à une composition pharmaceutique destinée à traiter ou à prévenir l'incontinence urinaire sur la base d'un nouveau mécanisme d'action, et à un procédé de criblage pour identifier les composés à inclure dans ladite composition pharmaceutique à titre de principe actif. Pour ce faire, la composition pharmaceutique destinée à traiter ou à prévenir l'incontinence urinaire de stress ou l'incontinence mixte selon l'invention contient à titre de principe actif un composé ayant un effet d'activation du récepteur de mélatonine. La mélatonine, le rameltéon, l'agomélatine, le tasimeltéon, le TIK-301, et autres, peuvent être cités à titre de principe actif. L'invention utilise en outre un procédé de criblage pour identifier les composés à inclure dans la composition pharmaceutique destinée à traiter ou à prévenir l'incontinence urinaire de stress ou l'incontinence mixte, ledit procédé comprenant : une étape de mesure de l'activité du récepteur de mélatonine; une étape de mesure de la contraction d'un urètre excisé; et une étape de mesure de la pression urétrale interne.
(JA) 【課題】新規な作用機序に基づく尿失禁の治療又は予防用医薬組成物、及び、当該医薬組成物に有効成分として含有される化合物のスクリーニング方法を提供する。 【解決手段】本発明は、メラトニン受容体活性化作用を有する化合物を有効成分として含有する、腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物に関する。当該有効成分として、メラトニン、ラメルテオン、アゴメラチン、タシメルテオン又はTIK-301等が挙げられる。また、メラトニン受容体の活性化を測定する工程、摘出尿道の収縮を測定する工程、尿道内圧を測定する工程などからなる腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物に有効成分として含有される化合物のスクリーニング方法に関する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)